Siemens Healthineers: A Company at a Crossroads as Spin-Off Plans Take Shape

Siemens Healthineers plans a 2027 spin-off from parent Siemens AG, as diagnostics struggles offset strong imaging and cancer therapy growth, sending shares to a 52-week low.

The German medtech giant is navigating one of its most turbulent periods in recent memory. While its core imaging and cancer therapy businesses continue to hum along, a deepening crisis in diagnostics has forced management into a strategic overhaul that will reshape the company's structure for years to come.

A Leadership Shake-Up and a Roadmap to Independence

CEO Bernd Montag is wasting no time. Alongside the quarterly results, he announced a generational changing of the guard, with four senior executives exiting the company, including technology chief Peter Schardt. The management reshuffle is the opening act of a much bigger drama: the full separation of Siemens Healthineers from its parent.

The plan is to put a direct spin-off of 30% of Healthineers shares to Siemens shareholders to a vote at the annual general meeting in February 2027. A banking syndicate has already lined up the refinancing to make it happen. The move would effectively cut the cord with the Siemens AG mothership, which is also eyeing a final disposal of its remaining stake in early 2027.

Diagnostics Drags Down an Otherwise Solid Quarter

The operational picture is one of stark contrasts. The core imaging and Varian cancer therapy businesses posted robust growth of around 5% in the second quarter, helping lift group revenues to €5.7 billion. The imaging segment's margin is a standout at 22.4%, underpinned by the company's dominance in CT and MRI systems. The new DryCool MRI technology now accounts for nearly half of all global deliveries — a technological moat that competitors would struggle to cross.

But diagnostics remains the albatross. Structural changes in the Chinese market, where lower reimbursement rates and volume-based procurement are squeezing margins, have hit the segment hard. Revenues there fell 6.5%, and the company was forced to cut its full-year guidance for fiscal 2026. Management is now preparing a carve-out of the diagnostics unit, with CFO Jochen Schmitz overseeing the process to give the group maximum strategic flexibility.

Adjusted earnings per share slipped to €0.53. The company noted that without negative currency and tariff effects, operating profit growth would have been 16%.

The Stock Hits Rock Bottom

The market's verdict has been brutal. Shares closed at €33.50 on Friday, matching a 52-week low. The stock has lost nearly 25% of its value since the start of the year, and the discount to its five-year median P/E of 18.6x is now extreme. At 14.8x forward earnings for 2026, the valuation is pricing in a lot of pain.

Deutsche Bank analyst Falko Friedrichs remains on the sidelines with a "Hold" rating and a €42 price target. He points out that the company only beat expectations thanks to positive interest and tax effects — a dynamic that investors are unlikely to reward.

Two Paths, Two Philosophies

The contrast with rival Philips is instructive. While Healthineers is trading at a discount to its historical average, Philips has been enjoying a tailwind from confirmed guidance and analyst upgrades. The Dutch group's stock closed at €22.65, buoyed by a 6% rise in comparable orders and a new share buyback program launched on May 8.

On quality metrics, Healthineers has the edge. Its return on invested capital of 11.1% and adjusted EBITA margin of 14.7% comfortably beat Philips' 8.2% and 9.0%, respectively. Net debt to EBITDA is also healthier at 1.9x versus Philips' 2.3x.

But Philips offers a more compelling near-term value proposition. Its PEG ratio of 0.95 suggests the projected recovery is not yet fully priced in, compared to Healthineers' 1.15. The Dutch company's confirmed outlook — 3% to 4.5% comparable sales growth with an adjusted EBITA margin of 12.5% to 13.0% — stands out in a quarter when competitors were cutting forecasts.

What Lies Ahead

For Healthineers, the next major test comes this summer with third-quarter results. The market will be watching to see if the core business can maintain its current momentum and whether the diagnostics restructuring is starting to bear fruit. Analysts expect the group's operating margin to improve from the current 9.1% to around 11% over the medium term.

The China risk remains significant — around 10% of group sales are exposed to a market undergoing structural reassessment. Management has already raised its estimated inflation impact by €0.05 per share.

For patient value investors, the current share price at €33.50 may represent an attractive entry point into a business with formidable competitive advantages in imaging. The diagnostics spin-off could act as a catalyst for re-rating within the next twelve months. But for those seeking momentum and operational delivery today, Philips currently offers a more convincing story. Healthineers is asking the market to wait — and in this environment, patience is a scarce commodity.